329 related articles for article (PubMed ID: 9656777)
21. Mini-ICE regimen allows mobilization of peripheral blood progenitor cells in a patient with chronic myelogenous leukemia failing the ICE protocol.
Salar A; Sureda A; Menéndez B; Sierra J
Haematologica; 2000 Mar; 85(3):326-7. PubMed ID: 10702830
[No Abstract] [Full Text] [Related]
22. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
23. Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon.
McBride NC; Cavenagh JD; Newland AC; Lillington DM; Murrell C; Kelsey SM
Bone Marrow Transplant; 2000 Dec; 26(11):1165-72. PubMed ID: 11149726
[TBL] [Abstract][Full Text] [Related]
24. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
25. Mini-ICE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis.
Sureda A; Petit J; Brunet S; Boqué C; Aventín A; Martino R; González JR; Amill B; Larriba I; Blanco A; Martín-Henao GA; Sierra J; Grañena A
Bone Marrow Transplant; 1999 Dec; 24(12):1285-90. PubMed ID: 10627636
[TBL] [Abstract][Full Text] [Related]
26. Autologous stem cell transplantation for advanced acute myeloid leukemia.
Linker CA; Damon LE; Ries CA; Navarro WA; Case D; Wolf JL
Bone Marrow Transplant; 2002 Feb; 29(4):297-301. PubMed ID: 11896426
[TBL] [Abstract][Full Text] [Related]
27. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.
Ruiz-Argüelles GJ; Gomez-Almaguer D; Steensma DP
Am J Hematol; 2012 Sep; 87(9):941. PubMed ID: 22674687
[No Abstract] [Full Text] [Related]
28. Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia.
Heim D; Friess D; Christen S; Stüssi G; Meyer-Monard S; Tichelli A; Passweg JR; Gratwohl A
Leukemia; 2006 May; 20(5):898-900. PubMed ID: 16525490
[No Abstract] [Full Text] [Related]
29. ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia.
Carella AM; Frassoni F
Br J Haematol; 1996 Oct; 95(1):213-5. PubMed ID: 8857964
[No Abstract] [Full Text] [Related]
30. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
31. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?
Vellenga E; van Putten WL; Boogaerts MA; Daenen SM; Verhoef GE; Hagenbeek A; Jonkhoff AR; Huijgens PC; Verdonck LF; van der Lelie J; Schouten HC; Gmür J; Wijermans P; Gratwohl A; Hess U; Fey MF; Löwenberg B
Bone Marrow Transplant; 1999 Jun; 23(12):1279-82. PubMed ID: 10414916
[TBL] [Abstract][Full Text] [Related]
32. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
33. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
Petzer AL; Hochenburger E; Haun M; Duba HCh; Grünewald K; Hoflehner E; Sill H; Linkesch W; Gastl G; Gunsilius E
J Hematother Stem Cell Res; 2002 Apr; 11(2):293-300. PubMed ID: 11983100
[TBL] [Abstract][Full Text] [Related]
34. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
[TBL] [Abstract][Full Text] [Related]
35. Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Carella AM; Simonsson B; Link H; Lennard A; Boogaerts M; Gorin NC; Tomas-Martinez JF; Dabouz-Harrouche F; Gautier L; Badri N
Br J Haematol; 1998 Apr; 101(1):111-8. PubMed ID: 9576191
[TBL] [Abstract][Full Text] [Related]
36. [Mobilization of Ph-negative hematopoietic stem cells using rhG-CSF in patients with chronic myeloid leukemia treated with interferon-alfa. Experience of the Clinic Hospital of Barcelona].
Carreras E
Sangre (Barc); 1997 Apr; 42 Suppl 1():24-6. PubMed ID: 9381296
[No Abstract] [Full Text] [Related]
37. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
38. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
Donato ML; Gershenson D; Ippoliti C; Wharton JT; Bast RC; Aleman A; Anderlini P; Gajewski JG; Giralt S; Molldrem J; Ueno N; Lauppe J; Korbling M; Boyer J; Bodurka-Bevers D; Bevers M; Burke T; Freedman R; Levenback C; Wolf J; Champlin RE
Bone Marrow Transplant; 2000 Jun; 25(11):1137-40. PubMed ID: 10849525
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217
[TBL] [Abstract][Full Text] [Related]
40. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
